A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults

References

• Organization WH. Global report on diabetes. Geneva, Switzerland 2016.
   Google Scholar
• Prevention CfDCa. National diabetes statistics report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services2017.
   Google Scholar
• Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
   PubMed Web of Science ®Google Scholar
• Papatheodorou K, Banach M, Bekiari E, et al.. Complications of diabetes 2017. J Diabetes Res. 2018;2018:3086167.
   PubMed Web of Science ®Google Scholar
• Barrett AM, Lucero MA, Le T, et al.. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(Suppl 2):S50–62.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kratz KM, Karnes JL, et al.. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the rochester diabetic neuropathy study. Neurology. 1993;43(4):817–824. DOI:10.1212/WNL.43.4.817
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Albers JW, Andersen H, et al.. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. DOI:10.1002/dmrr.1226
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al.. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. DOI:10.2337/dc10-1303
   PubMed Web of Science ®Google Scholar
• Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle?. Curr Diab Rep. 2012;12(4):403–413.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Nevoret ML, Casellini C, et al.. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747–787.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–849.
   PubMed Web of Science ®Google Scholar
• Kaku M, Vinik A, Simpson DM. Pathways in the diagnosis and management of diabetic polyneuropathy. Curr Diab Rep. 2015;15(6):609.
   PubMed Web of Science ®Google Scholar
• Blair HA. Capsaicin 8% dermal patch: a review in peripheral neuropathic pain. Drugs. 2018;78(14):1489–1500.
   PubMed Web of Science ®Google Scholar
• Babbar S, JF M, MS M, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502–510.
   PubMed Web of Science ®Google Scholar
• Peppin JF, Majors K, Webster LR, et al.. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–392.
   PubMedGoogle Scholar
• Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain. 1990;41(1):61–69.
   PubMed Web of Science ®Google Scholar
• Dray A. Mechanism of action of capsaicin-like molecules on sensory neurons. Life Sci. 1992;51(23):1759–1765.
   PubMed Web of Science ®Google Scholar
• Papagianni A, Siedler G, Sommer C, et al.. 8% patch reversibly reduces A-delta fiber evoked potential amplitudes. Pain Rep. 2018;3(2):e644.
   PubMedGoogle Scholar
• Chanda S, Mould A, Esmail A, et al.. Toxicity studies with pure trans-capsaicin delivered to dogs via intravenous administration. Regul Toxicol Pharmacol. 2005;43(1):66–75.
   PubMed Web of Science ®Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.
   PubMed Web of Science ®Google Scholar
• Bonezzi C, Costantini A, Cruccu G, et al.. Capsaicin 8% dermal patch in clinical practice: an expert opinion. Expert Opin Pharmacother. 2020;21(11):1377–1387. DOI:10.1080/14656566.2020.1759550
   PubMed Web of Science ®Google Scholar
• Simpson DM, Brown S, Tobias J, et al.. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–2313.
   PubMed Web of Science ®Google Scholar
• Chanda S, Bashir M, Babbar S, et al.. In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos. 2008;36(4):670–675.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al.. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. DOI:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al.. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. DOI:10.1186/s12883-016-0752-7
   PubMed Web of Science ®Google Scholar
• Brown S, Simpson DM, Moyle G, et al.. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;10(1):5. DOI:10.1186/1742-6405-10-5
   PubMed Web of Science ®Google Scholar
• Webster LR, Tark M, Rauck R, et al.. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol. 2010;10(1):92.
   PubMedGoogle Scholar
• Irving G, Backonja M, Rauck R, et al.. Vanhove GF. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(2):101–107.
   PubMed Web of Science ®Google Scholar
• Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al.. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(9):162. DOI:10.1007/s12032-017-1015-1
   PubMed Web of Science ®Google Scholar
• van Nooten F, Treur M, Pantiri K, et al.. 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803e18.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al.. Repeat treatment with capsaicin 8% patch (179mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Current Med Res Opinion. 2019;Volume. ; 2(12):388–401. doi:10.15520/jcmro.v2i12.242
   Google Scholar
• Galvez R, Navez ML, Moyle G, et al.. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin J Pain. 2017;33(10):921–931. DOI:10.1097/AJP.0000000000000473
   PubMed Web of Science ®Google Scholar
• Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–683.
   PubMed Web of Science ®Google Scholar
• Mankowski C, Poole CD, Ernault E, et al.. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17(1):80. DOI:10.1186/s12883-017-0836-z
   PubMedGoogle Scholar
• Lanteri-Minet M, Perrot S. QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France. Curr Med Res Opin. 2019;35(3):417–426.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drug approval package: QUTENZA (capsaicin) patch 1–17.
   Google Scholar